Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Apr;40(4):988–991. doi: 10.1128/aac.40.4.988

Levels of recombinant human granulocyte colony-stimulating factor in serum are inversely correlated with circulating neutrophil counts.

H Takatani 1, H Soda 1, M Fukuda 1, M Watanabe 1, A Kinoshita 1, T Nakamura 1, M Oka 1
PMCID: PMC163244  PMID: 8849265

Abstract

Recombinant human granulocyte colony-stimulating factor (rhG-CSF) is effective in countering chemotherapy-induced neutropenia. However, serum rhG-CSF levels cannot be maintained throughout the course of rhG-CSF therapy. The drop in serum rhG-CSF levels may vary with the duration of rhG-CSF administration or with the circulating neutrophil counts. We investigated the relationship between serum G-CSF levels and circulating neutrophil counts and the pharmacokinetics of rhG-CSF for patients with lung cancer who had been treated with myelosuppressive chemotherapy and then with subcutaneous rhG-CSF (lenograstim, 2 micrograms per kg of body weight per day). Twelve patients were randomly assigned to four groups with different rhG-CSF therapy schedules. Serum G-CSF levels were measured by an enzyme immunoassay method. Serum G-CSF levels during the rhG-CSF therapy greatly exceeded endogenous G-CSF levels and were mainly due to the presence of exogenous rhG-CSF rather than increased levels of endogenous G-CSF. Despite the duration of rhG-CSF administration, serum G-CSF levels during rhG-CSF therapy were inversely correlated with circulating neutrophil counts (r2 = 0.73, P < 0.0001). The value for the area under the concentration-time curve of rhG-CSF on the day of neutrophilia was lower than that on the day of neutropenia (P < 0.05). Our results suggest that the fall in serum G-CSF levels during rhG-CSF therapy may result from increased clearance and/or decreased absorption of rhG-CSF, two processes related to circulating neutrophil counts.

Full Text

The Full Text of this article is available as a PDF (200.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bartocci A., Mastrogiannis D. S., Migliorati G., Stockert R. J., Wolkoff A. W., Stanley E. R. Macrophages specifically regulate the concentration of their own growth factor in the circulation. Proc Natl Acad Sci U S A. 1987 Sep;84(17):6179–6183. doi: 10.1073/pnas.84.17.6179. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bukowski R. M., Budd G. T., Gibbons J. A., Bauer R. J., Childs A., Antal J., Finke J., Tuason L., Lorenzi V., McLain D. Phase I trial of subcutaneous recombinant macrophage colony-stimulating factor: clinical and immunomodulatory effects. J Clin Oncol. 1994 Jan;12(1):97–106. doi: 10.1200/JCO.1994.12.1.97. [DOI] [PubMed] [Google Scholar]
  3. Cebon J. S., Bury R. W., Lieschke G. J., Morstyn G. The effects of dose and route of administration on the pharmacokinetics of granulocyte-macrophage colony-stimulating factor. Eur J Cancer. 1990;26(10):1064–1069. doi: 10.1016/0277-5379(90)90053-v. [DOI] [PubMed] [Google Scholar]
  4. Cebon J., Layton J. E., Maher D., Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol. 1994 Feb;86(2):265–274. doi: 10.1111/j.1365-2141.1994.tb04725.x. [DOI] [PubMed] [Google Scholar]
  5. Demetri G. D., Griffin J. D. Granulocyte colony-stimulating factor and its receptor. Blood. 1991 Dec 1;78(11):2791–2808. [PubMed] [Google Scholar]
  6. Eguchi K., Shinkai T., Sasaki Y., Tamura T., Ohe Y., Nakagawa K., Fukuda M., Yamada K., Kojima A., Oshita F. Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer. Jpn J Cancer Res. 1990 Nov;81(11):1168–1174. doi: 10.1111/j.1349-7006.1990.tb02530.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Layton J. E., Hockman H., Sheridan W. P., Morstyn G. Evidence for a novel in vivo control mechanism of granulopoiesis: mature cell-related control of a regulatory growth factor. Blood. 1989 Sep;74(4):1303–1307. [PubMed] [Google Scholar]
  8. Ludwig H., Fritz E., Leitgeb C., Pecherstorfer M., Samonigg H., Schuster J. Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994 Aug 15;84(4):1056–1063. [PubMed] [Google Scholar]
  9. Motojima H., Kobayashi T., Shimane M., Kamachi S., Fukushima M. Quantitative enzyme immunoassay for human granulocyte colony stimulating factor (G-CSF). J Immunol Methods. 1989 Mar 31;118(2):187–192. doi: 10.1016/0022-1759(89)90005-7. [DOI] [PubMed] [Google Scholar]
  10. Mountain C. F. A new international staging system for lung cancer. Chest. 1986 Apr;89(4 Suppl):225S–233S. doi: 10.1378/chest.89.4_supplement.225s. [DOI] [PubMed] [Google Scholar]
  11. Nicola N. A., Peterson L., Hilton D. J., Metcalf D. Cellular processing of murine colony-stimulating factor (Multi-CSF, GM-CSF, G-CSF) receptors by normal hemopoietic cells and cell lines. Growth Factors. 1988;1(1):41–49. doi: 10.3109/08977198809000245. [DOI] [PubMed] [Google Scholar]
  12. Ota K., Ariyoshi Y., Fukuoka M., Furuse K., Niitani H. [Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for lung cancer. rG.CSF Cooperation Study Group]. Gan To Kagaku Ryoho. 1990 Jan;17(1):65–71. [PubMed] [Google Scholar]
  13. Pauksen K., Elfman L., Ulfgren A. K., Venge P. Serum levels of granulocyte-colony stimulating factor (G-CSF) in bacterial and viral infections, and in atypical pneumonia. Br J Haematol. 1994 Oct;88(2):256–260. doi: 10.1111/j.1365-2141.1994.tb05015.x. [DOI] [PubMed] [Google Scholar]
  14. Redman B. G., Flaherty L., Chou T. H., Kraut M., Martino S., Simon M., Valdivieso M., Groves E. Phase I trial of recombinant macrophage colony-stimulating factor by rapid intravenous infusion in patients with cancer. J Immunother (1991) 1992 Jul;12(1):50–54. doi: 10.1097/00002371-199207000-00006. [DOI] [PubMed] [Google Scholar]
  15. Soda H., Oka M., Fukuda M., Kinoshita A., Sakamoto A., Araki J., Fujino S., Itoh N., Watanabe K., Kanda T. Optimal schedule for administering granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol. 1996;38(1):9–12. doi: 10.1007/s002800050440. [DOI] [PubMed] [Google Scholar]
  16. Stute N., Santana V. M., Rodman J. H., Schell M. J., Ihle J. N., Evans W. E. Pharmacokinetics of subcutaneous recombinant human granulocyte colony-stimulating factor in children. Blood. 1992 Jun 1;79(11):2849–2854. [PubMed] [Google Scholar]
  17. Tanaka H., Tokiwa T. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res. 1990 Oct 15;50(20):6615–6619. [PubMed] [Google Scholar]
  18. Watari K., Asano S., Shirafuji N., Kodo H., Ozawa K., Takaku F., Kamachi S. Serum granulocyte colony-stimulating factor levels in healthy volunteers and patients with various disorders as estimated by enzyme immunoassay. Blood. 1989 Jan;73(1):117–122. [PubMed] [Google Scholar]
  19. Wright D. G., Meierovics A. I., Foxley J. M. Assessing the delivery of neutrophils to tissues in neutropenia. Blood. 1986 Apr;67(4):1023–1030. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES